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ABSTRACT The transcriptional regulator p53 plays an essential role in tumor suppression. Accordingly, it is foundmutated, and
its activity is reduced, in many human cancers. Recent reports show that some cancers are characterized by a loss of function of
wild-type p53, which, in several cases, accumulates in intracellular aggregates. Although the nature of such aggregates is still
unclear, recent evidence indicates that the p53 C-terminal and core domains can undergo amyloid aggregation in vitro under mild
denaturing conditions, although no information is available on the largely unstructured N-terminal transactivation domain. We
therefore decided to investigate the amyloid propensity of the acidic unfolded 1–63 fragment of the transactivation domain,
cloned, expressed, and puriﬁed from a bacterial strain. Here we show that, when exposed to acidic pH, the 1–63 fragment forms
thioﬂavine T-positive aggregates whose amyloid nature was conﬁrmed by Fourier transform infrared spectroscopy analysis,
atomic force microscopy, and x-ray diffraction. These aggregates were shown to be cytotoxic to human SH-SY5Y cells by 3-(4,
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction, lactate dehydrogenase release, and caspase-3 activity
assays. These results add new signiﬁcant details to the picture describing the propensity of single domains of p53 to aggregate,
further suggesting that, under suitable destabilizing conditions, the whole protein may aggregate into amyloid assemblies in vivo.
INTRODUCTION
The tumor suppressor protein p53 is a 393-amino acid
phosphoprotein containing a single zinc ion whose homotet-
ramer plays a critical role as a transcriptional enhancer in cell
cycle control and apoptotic activation in response to DNA
damage (1,2). The key antitumoral role of p53 is supported
by the fact that it is mutated in around 50% of human cancers
(3); indeed, p53 inactivation by specific mutations or inter-
action with cellular proteins appears to be a critical step in the
origin of many cancers, thus making this protein a major
target for anticancer therapy.
The three-dimensional structure of p53 is organized into
three domains. The unstructured N-terminal domain (resi-
dues 1–93) harbors an acidic transactivation domain (resi-
dues 1–62), where the binding site for mdm2 (an E3 ubiquitin
ligase (4)) is located, and a proline-rich domain (residues 63–
93). The DNA-binding core (residues 102–292) is the main
domain responsible for p53-DNA interaction. Finally, the
C-terminal domain (residues 293–393) contains a tetrameri-
zation domain and a regulatory domain. p53 displays a lim-
ited structural stability and contains large regions
substantially devoid of ordered structure (5) with high con-
formational flexibility. Although the solution and x-ray
structures of the DNA-binding domain and the tetrameriza-
tion domain have been determined (6,7), there is a substantial
lack of structural and biophysical information on the full-
length protein as well as on N-terminal domain. In particular,
the latter appears completely disordered with the typical
features of the natively unfolded proteins (8).
Tumors involving p53 impairment can also be indepen-
dent of the presence of specific p53 mutations. In fact, cells
expressing wild-type p53 can contain an inactive form of the
protein, allowing malignancy to arise. In these cells p53 in-
activation can result, at least in part, from the loss of the
bound zinc, whose deleterious effect on protein stability and
activity is amplified by subsequent aggregation (9). The zinc-
free p53 folding variant displays dominant negative effects
that are able to drive the active, wild-type protein into an
inactive mutant conformation (10) through a process with
some similarity to prion amplification. Actually, accumula-
tion of wild-type inactive p53 has been described in various
cancers including neuroblastoma, retinoblastoma, and breast
and colon cancers (11,12). In these cells, p53 is aggregated
(13) in large cytoplasmic and/or nuclear deposits (11) pos-
sibly arising from a conformational change of the protein
(14). It is not known whether the p53 found in these aggre-
gates displays amyloid-like structure, but this possibility
should be considered.
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Amyloidoses are ;25 protein-misfolding diseases of the
degenerative type affecting either the central nervous system
or peripheral tissues and organs; they include Alzheimer’s,
Parkinson’s, and prion diseases, type 2 diabetes, and several
systemic amyloidoses (15). Each of these conditions is char-
acterized by the intracellular and/or extracellular presence,
in the affected tissues, of fibrillar deposits of polymers of 1 of
25 peptides or proteins, each characteristic of a specific dis-
ease (16). The presence of amyloid fibrils is a key feature
of amyloid diseases and is considered a main cause of the
clinical signs (17). Amyloid fibrils arise from a nucleation-
polymerization process on a destabilized peptide/protein; de-
stabilization can follow mutations, chemical modifications,
overexpression, or any impairment of peptide/protein degra-
dation by the ubiquitin proteasome pathway (17,18). Despite
the structural heterogeneity of their monomeric constituents,
amyloid fibrils share surprisingly similar structural features. In
fact, their key signature is the presence of an ordered b-struc-
ture-rich core in which each monomer contributes two or more
b-strands that result in a continuous double parallel or anti-
parallelb-sheet propagating along themain axis of the fibril and
in which each b-strand runs perpendicular to the fibril (16,19).
Presently, amyloid diseases are considered substantially
gain-of-function conditions because cell damage is thought
to arise from the acquired ability of the destabilized mono-
mers to polymerize into toxic assemblies rather than from the
loss of their biological function (19,20). Currently, the gen-
erally accepted idea is that the true cytotoxic species are not
mature amyloid fibrils but their oligomeric precursors, often
known as prefibrillar aggregates or protofibrils. An increas-
ingly growing number of data show that prefibrillar aggre-
gates are unstable species that interact with cell membranes
and other cell components impairing their integrity and/or
function. In particular, structural alteration of the cell mem-
branes with disruption of their selective permeability, re-
sulting in free calcium balance and redox homeostasis
derangement (21), is considered a key biochemical modifi-
cation in most amyloid diseases (16).
Because of the lack of data on either the aggregation po-
tential of the p53 N-terminal domain, particularly the 1–62
transactivation domain, or the mechanisms of cytotoxicity, if
any, of its aggregates, we sought to provide information on
these topics by cloning, expressing, and purifying the p53
1–63 N-terminal domain (p53(1–63)). The aggregation pro-
pensity of the latter was investigated together with the mor-
phological features and cytotoxicity of the differing
aggregates arising during the fibrillization path. Our data
show that, similarly to the core domain and the tetrameriza-
tion domain (both containing unstructured regions), the p53
unstructured N-terminal domain can aggregate in amyloid
assemblies exhibiting cytotoxic features. These data complete
those previously reported on the aggregation potential of the
p53 domains supporting a possible role of the N-terminal
domain as a trigger of p53 aggregation in the highly crowded
intracellular environment.
MATERIALS AND METHODS
Materials
The primers for PCR amplification were synthesized by Genenco (Florence,
Italy). HotStartTaq mix was from Qiagen GmbH (Hilden, Germany). Re-
striction enzymes were from Invitrogen (Carlsbad, CA). isopropyl-b-D-thi-
ogalactopyranoside was from Inalco (Milan, Italy). Sepharose-GSH affinity
resin was from Pharmacia (Piscataway, NJ). The CytoTox-ONE Homoge-
neous Membrane Integrity Assay was from Promega (Madison, WI). The
Ac-DEVD-AMC caspase-3 fluorometric substrate and Ac-DEVD-CHO
caspase-3 inhibitor were from Biomol (Plymouth Meeting, PA). Rabbit
polyclonal anti-p53 (FL-393) antibody was from Santa Cruz Biotechnology
(Santa Cruz, CA). Peroxidase-conjugated antirabbit antibody was from
Chemicon (Temecula, CA). SuperSignal West Pico Chemiluminescent
Substrate was from Pierce (Rockford, IL). All other reagents, media, en-
zymes and inhibitors were from Sigma Chemical (St. Louis, MO).
Cloning and puriﬁcation of the (1–63) p53
N-terminal fragment
The pUC18p53 plasmid containing the gene coding for whole-length human
p53 was kindly provided by Prof. Nobua Tsuchida, Dept. of Molecular
Cellular Oncology andMicrobiology, TokyoMedical and Dental University.
PCR amplification of the DNA fragment corresponding to residues 1–63 of
the whole p53 gene product was carried out using the direct primer 59-
AAAGGGGGATCCATGGAGGAGCCGCAGTCAGATCCT-39 containing
the restriction site for BamHI and the reverse primer 59-AAAAGGG-
AATTCTCAAGCTTCATCTGGACCTGGGTCT-39 containing the re-
striction site for EcoRI; 10 pmol of each primer was added to 20 ng of
template DNA and 12.5 mL of 23 PCR HotStartTaq mix in a final volume
of 25 ml.
The fragment resulting from PCR amplification (95C for 15 min for hot
start, followed by 25 cycles consisting of 95C for 1.0 min, 64C for 1.0 min,
72C for 1.0 min) was digested with BamHI and EcoRI and ligated into
pGEX-2T vector downstream and in frame with glutathione S-transferase.
Sequence determination performed by BMR Genomics (Padova, Italy)
confirmed the integrity of the cloned fragment.
Fusion protein expression was performed in E. coli BL21 cells trans-
formed with the pGEX-2T(1–63) plasmid. Cells were grown overnight at
37C in LB medium, diluted 1:10 in fresh medium, and treated with 0.1 mM
isopropyl-b-D-thiogalactopyranoside for 4.0 h for the induction of fusion
protein expression when they reached an OD of 0.6 at 600 nm. Bacterial cells
were centrifuged at 4000 rpm for 15 min at 4.0C, and the pellet was re-
suspended in a volume of PBS (20mMNa2HPO4, pH 7.3, 250mMNaCl, 1.0
mM EDTA, 1.0 mM b-mercaptoethanol, 0.1 mM phenylmethylsulphonyl
fluoride (PMSF)) corresponding to 1% of the cell culture volume. Cells were
lysed by incubation for 30 min in ice in the presence of 44 U/ml of lysozyme
and 0.1% Triton X-100, followed by sonication (50 kHz and 60 W for 30 s,
six pulses), and debris was removed by centrifugation at 16,000 rpm for 40
min at 4.0C. The supernatant was loaded onto a Sepharose-GSH affinity
column and, after extensive washing with PBS and TBS (50 mM Tris-HCl
buffer, pH 8.0, 150 mM NaCl), an in-column digestion of the fusion protein
was performed by incubating the resin overnight in the presence of 50 U of
human thrombin. p53(1–63) was then eluted from the column and concen-
trated by ultrafiltration to 3.0 mg/ml. Protein concentration was determined
by UV absorption at 280 nm using an extinction coefficient of 4.17 (1.0 mg/
ml, 1.0-cm optical path). Protein purity and quality were checked by SDS-
PAGE (silver staining), electrospray mass spectrometry, and amino acid
analysis, confirming the expected amino acid sequence GSMEEPQSDPS-
VEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFT-
EDPGPDEA, corresponding to aMr¼ 7.2 kDa and an isoelectric pH of 3.28.
The Gly-Ser dipeptide present at the N-terminus results from thrombin
cleavage of the fusion protein cloned in pGEX-2T.
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Th-T assay
The p53(1–63) bulk solution (3.0 mg/ml) was diluted to 0.4 mg/ml in 20 mM
citrate buffer at different pH values (3.0, 3.3, 3.6, 4.0) (assay buffer) and
incubated at 25C or 4.0C. Then, 60 ml of this solution was withdrawn at
different incubation times and mixed with 440 ml of 25 mM ThT in 25 mM
phosphate buffer, pH 6.0. In some experiments the aggregation mixture was
centrifuged at 18,000 rpm for 5.0 min, and the supernatant was assayed for
ThT binding. Sample fluorescence wasmeasured at 25C (440Ex/485Em) (22)
in a 2 3 10 mm path-length cell using a Perkin-Elmer LS 55 spectrofluo-
rimeter (Wellesley, MA) equipped with a thermostated cell holder connected
to a Haake F8 water-bath (Karlsruhe, Germany).
FT-IR spectroscopy
The p53(1–63) solution was incubated at 0.4 mg/ml in 20 mM citrate buffer,
pH 3.0, at 25C for increasing time periods. Peptide aggregates were ly-
ophilized and resuspended in D2O (minimum 99.96 atom%D) at 6.7 mg/ml,
and 15-ml aliquots of the suspension were placed between CaF2 windows
using a 6.0-mm spacer and analyzed by a Jasco 4200 FT-IR spectrometer.
Each spectrum was obtained by coadding 100 interferograms at a spectrum
resolution of 4.0 cm1. The spectrum of the native p53(1–63) was obtained
by lyophilizing a solution of 100mg of the protein in 50 mMTris-HCl buffer,
pH 8.0, containing 150 mM NaCl followed by dissolution of the lyophilized
peptide in 15 ml D2O for FT-IR analysis. Blank analysis was carried out by
lyophilizing and redissolving the buffers in D2O before FT-IR.
ANS ﬂuorescence
Aliquots of the p53(1–63) aggregation mixture (0.4 mg/ml in 20 mM citrate
buffer, pH 3.0, at 25C) were withdrawn at various time points and mixed
into a cuvette containing 450ml of 55mMANS in citrate buffer (final protein
concentration: 0.07 mg/ml). Samples were excited at 380 nm, and emission
was registered between 410 and 630 nm. At any time point, aliquots of the
reaction mixture were also centrifuged at 18,000 rpm for 5.0 min, and su-
pernatant and pellet were separately assayed for their ability to bind ANS.
p53(1–63) native peptide was similarly assayed for its ability to bind ANS in
50 mM Tris-HCl, pH 8.0, containing 150 mM NaCl.
Dot-blot analysis
p53(1–63) was incubated in 20mM citrate buffer, pH 3.0, for 30min at 25C;
then an aliquot of the mixture was centrifuged at 18,000 rpm for 5.0 min, and
different amounts of the supernatant were spotted onto a nitrocellulose
membrane together with identical quantities of total p53(1–63). As a positive
control, corresponding amounts of whole-length p53 were similarly applied
to the membrane, and 1.0 mg of an unrelated peptide was used as a negative
control. After incubation with anti-p53, peroxidase-conjugated antirabbit
antibodies and a chemiluminescent substrate, the image was acquired with a
ChemiDoc system (Bio-Rad, Hercules, CA).
AFM
A 0.4 mg/ml p53(1–63) solution was incubated at 4.0C in 20 mM citrate
buffer, pH 3.0. Aliquots of this solution were withdrawn at fixed time in-
tervals and diluted 100 times with bidistilled water; 20-ml aliquots of the
diluted sample were deposited on a freshly cleaved mica substrate and dried
under a gentle nitrogen flux. Dilution of the sample was required to avoid salt
crystallization. Tapping-mode AFM images were acquired in air using a
Dimension 3000 microscope (Digital Instruments-Veeco, Santa Barbara,
CA) equipped with a ‘‘G’’ scanning head (maximum scan size 100 mm) and
driven by a Nanoscope IIIa controller and a Multimode Scanning Probe
Microscope (Digital Instruments-Veeco), equipped with an ‘‘E’’ scanning
head (maximum scan size 10 mm) and driven by a Nanoscope IV controller.
Single-beam uncoated silicon cantilevers (type RTESPA, Veeco, and type
OMCL-AC160TS, Olympus, Tokyo, Japan) were used. The drive frequency
was around 300 kHz; the scan rate was between 0.3 and 0.8 Hz.
Aggregate size was measured from the height in cross section of topo-
graphic AFM images. Because sample drying results in a reduction of ag-
gregate size with respect to fully hydrated conditions, the values reported in
the Results section should be corrected by taking this effect into account. The
correction factor was evaluated to be 1.4 from the comparison of globular
proteins imaged in air and under liquid. Other factors that may affect the
measured size are the presence of amorphous material partially embedding
the aggregate and aggregate flattening on the mica substrate. The aggregate
width was measured at the full aggregate height; because width values are
affected by the tip size, they should be considered only as a rough estimate.
X-ray ﬁbril diffraction
p53(1–63) fibrils obtained after 1 month of incubation at 25C in 20 mM
sodium citrate buffer, pH 3.0, were centrifuged at 3500 rpm and 21C for
10 min. The resulting pellet was collected and inserted into a 1.0-mm cap-
illary with an open end. The capillary was placed into a support of expanded
polystyrene to avoid its rupture and gently centrifuged; finally, the super-
natant was removed. The pellet in the capillary was exposed to air to achieve
solvent evaporation for;1 week. Then the capillary was exposed to x rays at
room temperature using a MAR Research (Norderstedt, Germany) 345
imaging-plate detector coupled to a Rigaku (Tokyo, Japan) RU-H3R rotating-
anode generator, using monochromatic Cu Ka radiation. Fibril diffraction
image analysis and spacing estimates were achieved using the Mosflm
program (23).
Cytotoxicity assay
Human SH-SY5Y neuroblastoma cells were obtained from the American
Type Culture Collection (Manassas, VA) and cultured in 1:1 Ham’s
F-10:DMEM medium supplemented with 10% fetal calf serum, 3.0 mM
glutamine, 100 mg/ml streptomycin, and 100 units/ml penicillin, in a 5.0%
CO2 humidified atmosphere at 37C. Aggregate cytotoxicity was assessed by
the MTT reduction inhibition assay (24). Cells were plated on 96-well plates
at a density of 6000 cells/well in 200ml of fresh medium. After 72 h, the cells
were exposed for 24 h to different concentrations (ranging from 0.4mM to 12
mM) of p53(1–63) aggregates precipitated by centrifugation (18,000 rpm for
5.0 min) and resuspended in 50 ml of fresh medium. At the end of the in-
cubation, the cell culture medium was removed, and the cells were incubated
for 2.0 h with 100ml of a 0.5 mg/mlMTT solution in DMEMwithout phenol
red. After incubation, cell lysis solution (100 ml/well: 20% SDS, 50% N,N-
dimethylformamide) was added, and the samples were incubated overnight at
37C in a humidified incubator. Blue formazan absorbance was measured at
570 nm using an automatic plate reader (Bio-Rad). Control experiments were
performed by exposing cells to the nonaggregated monomeric protein at a
final concentration of 12 mM for the same lengths of time.
Necrotic and apoptotic markers
Membrane integrity in cells exposed to p53(1–63) aggregates was evaluated
by measuring LDH release into the culture medium. LDH activity was
measured with the CytoTox-ONE homogeneous membrane integrity assay,
according to instructions provided by the manufacturer. The assay couples
the reduction of resazurin to resofurin, catalyzed by diaphorase, to the oxi-
dation of lactate to pyruvate, catalyzed by LDH. The intensity of the resulting
fluorescence (560Ex/590Em) is a measure of LDH activity in the sample.
Briefly, the cells, plated and cultured as described for the MTT reduction
assay, were treated for 24 h with 12 mM p53(1–63) aggregates aged for 100
min in 20 mM citrate buffer, pH 3.0, at 25C or 4.0C, resuspended in
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DMEM without phenol red and sodium pyruvate and supplemented with
5.0% fetal calf serum. The reagent was added to the culture medium, and the
increase in fluorescence emission was measured after 2.0 h using a Fluo-
roskan Ascent FL fluorescence plate reader (Thermo Scientific, Madison,
WI). For each sample, the fluorescence value was normalized with respect to
the ‘‘total LDH activity’’ determined after cell lysis.
The caspase-3 activity assay was carried out as follows. Cells were ex-
posed for 24 h to 12mMp53(1–63) aggregates obtained as for the LDH assay
and resuspended in complete medium. Control cells were treated with the
same concentration of soluble p53(1–63). After 24 h, the cells were lysed
with 20 mM Tris-HCl buffer, pH 7.4, containing 250 mM NaCl, 2.0 mM
EDTA, 0.1% Triton X-100, 5.0 mg/ml leupeptin, 5.0 mg/ml aprotinin, 0.5
mM PMSF, 4.0 mM vanadate, and 1.0 mMDTT for 20 min in ice. Lysis was
completed by sonication, and total protein content was determined in the
clarified lysate with the Bradford reagent. Then, 50 mg of total protein was
diluted in 0.5 ml of 50 mM HEPES-KOH buffer, pH 7.0, containing 10%
glycerol, 0.1% 3-[(3-cholamidopropyl)-dimethylammonium]-1-propane sul-
fonate, 2.0 mM EDTA, 10 mM DTT, in the presence of 50 mM Ac-DEVD-
AMC (caspase-3 fluorometric substrate). Incubation was carried out for 2.0 h
at 37C, and fluorescence values were recorded (380Ex/460Em). To determine
nonspecific substrate degradation, the same assay was performed by pre-
incubating samples for 15 min at 37C in the presence of 100 nMAc-DEVD-
CHO (caspase-3 inhibitor) before substrate addition.
Statistical analysis
Dunnett multiple-comparisons test was performed on data obtained from
MTT, LDH, and caspase-3 assays.
RESULTS
p53(1–63) forms ThT-positive aggregates in vitro
The p53(1–63) transactivation domain displays typical fea-
tures of the intrinsically unstructured proteins including a low
content of hydrophobic residues that are flanked, in se-
quence, by numerous acidic residues. These features inhibit
the formation of a hydrophobic core, disfavor the organiza-
tion of rigid secondary structure elements, and result in an
extended conformation caused by electrostatic repulsion
(25).
Initially, we determined the propensity of p53(1–63) to
form amyloid aggregates at pH values approaching its iso-
electric point (3.28), a condition known to favor protein-
protein interaction. The peptide (3.0 mg/ml in 50 mMTris-HCl
buffer, pH 8.0, 150 mMNaCl) was diluted to 0.4 mg/ml in 20
mM citrate buffer at differing pH values (3.0, 3.3, 3.6, 4.0)
and analyzed at 25C for its ability to bind ThT by moni-
toring the time-course of the increase of fluorescence at 485
nm (Fig. 1 A). ThT positivity is considered a strong indicator
of the presence of ordered aggregated material of amyloid
type (22). We controlled the citrate buffer so that the pH did
not change on addition of the peptide solution by mixing the
corresponding volumes of citrate and Tris-HCl buffers. We
found that p53(1–63) rapidly forms ThT-positive aggregates
in the 3.0–3.6 pH range; however, within the time scales of
our experiments, no significant aggregation was observed at
pH 4.0. The ThT fluorescence increase reached a plateau after
30 min of incubation. As expected, reducing the incubation
temperature to 4.0C resulted in a slower increase of ThT
fluorescence (Fig. 1 B), although the plateau value, reached at
these conditions in the 12- to 24-h interval, was substantially
unchanged, indicating that p53(1–63) aggregation is driven
mainly by entropic contributions as reported for the aggre-
gation of other proteins/peptides (26).
p53(1–63) forms ANS-positive aggregates
The hydrophobic dye ANS is a dye whose fluorescence is
greatly enhanced on binding to hydrophobic surfaces, dis-
playing a characteristic blue shift in its fluorescence maxi-
mum from 515 nm to 480 nm (27,28). ANS is largely used as
a probe to reveal the increased exposure of hydrophobic
surfaces that is characteristic of partially structured folding
intermediates and amyloid aggregates (27,28). As early as
FIGURE 1 ThT assay on p53(1–63). The peptide was incubated in 20
mM citrate buffered at pH 3.0 (black diamonds), 3.3 (white squares), 3.6
(white triangles), and 4.0 (crosses) at 25C for up to 120 min (A) or in 20
mM citrate buffer pH 3.0 at 4.0C (black squares) or 25C (white diamonds)
for up to 24 h (B). At regular time intervals aliquots were withdrawn from the
reaction mixtures and assayed for their ability to bind ThT. Fluorescence of
samples was normalized with respect to the fluorescence of a blank. These
are representative experiments of four giving qualitatively identical results.
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after 30 s of incubation of p53(1–63) at pH 3.0, we observed
an increase in ANS binding (Fig. 2 A) characterized by a pro-
nounced blue shift of the emission spectrum which increased
with aggregation. The supernatant obtained by centrifugation
of the aggregation mixture displayed no ANS-binding while
the pellet was strongly positive (Fig. 2 B), suggesting that the
early precipitation of p53(1–63) is associated to a progressive
exposure of hydrophobic clusters resulting from the structural
organization of the polypeptide chain.
Structural analysis of p53(1–63) aggregates
To gain more information on the structural features of the ag-
gregating peptide in the precipitate, we performed an FT-IR
analysis of the soluble and aggregated peptide. Aliquots of
p53(1–63) dissolved in 50 mM Tris-HCl buffer, pH 8.0, 150
mM NaCl, lyophilized, and dissolved in D2O, were analyzed
by FT-IR. The spectrum of this soluble form of the peptide
confirmed its partially unfolded nature, characterized by a
peak around 1640 cm1, although the presence of a peak at
1659 cm1 and of a minor one at 1631 cm1 indicated some
a-helix and b-sheet secondary structure (Fig. 3A). p53(1–63)
was then aged in the aggregation medium for various lengths
of time at 25C or 4.0C, lyophilized, and resuspended in
D2O. To better monitor the variations in the absorbance at
characteristic wavenumbers during the time course of ag-
gregation, the FT-IR spectra were first scaled to the same
area, and difference spectra were then calculated by sub-
tracting the spectrum of the native peptide from the spectrum
of the aggregated peptide (Fig. 3 B). Then the area of the
resulting D-absorbance peaks (taken above the baseline for
positive peaks and under the baseline for negative peaks) was
calculated (Fig. 3 C). The results of the FT-IR analysis re-
vealed a progressive increase of the absorbance around 1615
cm1 and 1683 cm1 that is typical of the intermolecular
b-sheet found in amyloid assemblies (29), paralleled by a
decrease in the absorbance around 1640 cm1, suggesting a
transition from disordered to ordered aggregates in the pre-
cipitate. The latter appeared to be slower for aggregates
grown at 4.0C than at 25C; nevertheless, after 4 days the
spectra of the peptide incubated at these different tempera-
tures are similar, indicating that the samples reached com-
parable states regardless of the temperature (Fig. 3 B).
Detailed peak analysis showed that after 100 min of in-
cubation in the aggregation medium, p53(1–63) displayed a
decrease of the unfolded structure with respect to the native
peptide, as shown by the negative peak in the 1637–1645
cm1 range in the difference spectrum. The absolute value of
this difference peak was higher for the aggregates obtained at
25C than for those obtained at 4.0C, in agreement with the
faster aggregation kinetics of the former (Fig. 3 C). At this
time, transitory increases in a-helix (as suggested by the
positive difference peaks in the 1648–1656 cm1 interval)
and in b-sheet nonamyloid and amyloid structures (as shown
by the positive difference peaks around 1635 and 1683 cm1,
respectively) are evident. After 3.0 h of incubation, the
contribution of unfolded, a-helix, and b-sheet nonamyloid
structures was reduced, whereas an increase in amyloid
b-structure (1615–1618 cm1 and 1678–1686 cm1) was
apparent. The slower kinetics of these changes at 4.0C than
at 25C is evident. In fact, at 25C, these peaks reach their
maxima at 3.0 h (Fig. 3 C), although after 4 days at either
4.0C or 25C, the difference spectra were similar and dis-
played a prevalence of amyloid structure over all other sec-
ondary structures.
Taken together, these data suggest that p53(1–63) aggre-
gation proceeds through the early precipitation of the peptide
that subsequently undergoes a progressive transition leading
it to acquire some amyloid structural features, a process
FIGURE 2 ANS test on p53(1–63). (A) The emission spectrum of ANS
without protein was acquired (1). The ANS spectrum was then acquired in
the presence of native p53(1–63) (2) or of p53(1–63) incubated in 20 mM
citrate buffer, pH 3.0, and assayed after 30 s (3), 30 min (4), or 1 h (5). (B)
The pellet and the supernatant obtained by centrifuging aliquots of the
reaction mixture were separately assayed for their ability to bind ANS by
measuring their emission at 480 nm (total, black diamonds; pellet, white
squares; supernatant, black triangles). The data are representative of three
experiments carried out under identical conditions, giving qualitatively
identical results.
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mainly driven by entropic contributions that apparently needs
a transient increase in the content of nonamyloid secondary
structure, as previously shown for other systems (26,30).
AFM used after p53(1–63) aggregation
Tapping-mode AFM was used to investigate the morpho-
logical features of the aggregates resulting from the incuba-
tion of p53(1–63) in citrate buffer at pH 3.0. Initially,
globular particles randomly present on the whole sample
surface were observed with height distribution peaking at 1.3
nm (not shown). When the correction factor for dehydration
effects (see Materials and Methods) is considered, this size
may correspond to the monomeric protein. At early aggre-
gation times (20 min), globular particles (Fig. 4 A) with an
average size of 3.1 6 0.1 nm (Fig. 4 A, inset) were present.
These globules displayed the tendency to assemble into short
beaded chains composed of several units at later (3.0 h) times
(Fig. 4 B) with a broader size distribution (Fig. 4 B, inset).
After 24 h, very thin filaments 0.5 nm high coexisted with
lenticular structures 4.0 nm high and 60–240 nmwide (Fig. 4,
C and D). The latter consisted of entangled filaments, as
shown in the amplitude image of Fig. 4 D, and these were
probably spheroidal structures deformed by the adhesion to
the mica substrate. Comparably similar structures were ob-
served in the path of aggregation of other amyloid-forming
proteins (31,32). Fibrillar structures 2.0 nm high were ob-
served after 10 days (not shown), whereas at longer incuba-
tion times (;1month), thicker fibrils, often supercoiled, were
found (Fig. 5 A). Accordingly, the size distribution of these
mature fibrils was bimodal, with peaks at 3.3 and 5.5 nm (Fig.
5 B), further indicating that they were formed by different
numbers of protofilaments.
p53(1–63) ﬁbrils display the shared
cross-b-amyloid structure under x-ray diffraction
It is known that in some cases protein aggregation results in
fibrillar assemblies in which the monomers substantially
maintain their native structure and are arranged differently
than in amyloid fibrils (33,34) even though their aggregates
display spectroscopic features of the amyloids such as ThT
and Congo red positivity. X-ray analysis reveals with full
reliability structural features, such as the cross-b-structure,
that are key signatures of amyloid fibrils. Therefore, p53(1–
63) fibrillar aggregates, obtained by incubating the protein in
20 mM sodium citrate buffer, pH 3.0, were sedimented in a
capillary and analyzed by x-ray diffraction. The x-ray dif-
fraction pattern (Fig. 5 C) is consistent with the presence of a
FIGURE 3 (A) FT-IR spectrum of p53(1–63) dissolved in 50 mM Tris-
HCl buffer, pH 8.0, containing 150 mM NaCl, lyophilized, and resuspended
in D2O. (B) Structural changes occurring during p53(1–63) aggregation
were determined by incubating the peptide in 20 mM citrate buffer, pH 3.0,
for increasing lengths of time at 4.0C or 25C. The FT-IR analysis was
carried out on the peptide lyophilized and resuspended in D2O. The spectra
were scaled to the same area, and difference spectra were calculated by
subtracting the spectrum of the native peptide from the spectrum of the
aggregated peptide at any time point. (C) For every D-absorbance spectrum,
the areas comprised into distinct wavenumber intervals, taken above the zero
line for positive D-absorbance peaks and below the zero line for negative
D-absorbance peaks, were calculated. The analysis was repeated three times,
giving closely similar results.
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cross-b-conformation typical of amyloid fibrils. In particular,
the diffraction pattern shows a strong reflection around 4.5 A˚,
corresponding to the hydrogen bonding distance between
consecutive b-strands in b-sheets, and a strong reflection
around 10 A˚, which indicates the sheet distance of the two
b-sheets propagating along each protofilament. These find-
ings definitely indicate that our fibrillar material is amyloid in
nature.
p53(1–63) aggregates are cytotoxic
p53(1–63) was aggregated at 25C or 4.0C for increasing
time periods. At the end of each incubation time, the aggre-
gates were recovered by centrifugation, suspended in com-
plete medium, and added to SH-SY5Y neuroblastoma cell
cultures at 12.0 mM final protein concentration for 24 h. The
stability of the aggregates during the time course of cell ex-
posure was confirmed by the ThT assay (data not shown).
The quantity of aggregates recovered after centrifugation was
evaluated by determining the amount of protein present in the
supernatant by Dot-blot analysis with anti-p53 antibodies,
confirming that no p53(1–63) remained in the supernatant
after aggregate centrifugation (not shown). Furthermore, a
ThT assay performed on the aggregate mixture and on the
supernatant (after aggregate precipitation) revealed that, al-
though the whole mixture was strongly ThT positive, no
positivity was detected in the supernatant (data not shown).
p53(1–63) aggregate cytotoxicity was determined by ex-
posing cultured human SH-SY5Y neuroblastoma cells to
protein aggregates aged for differing lengths of time. Control
experiments were conducted by exposing cells to 12.0 mM
p53(1–63) in its soluble form. The viability of the cells so
treated was assayed by the MTT reduction assay. Fig. 6 A
shows that the aggregates obtained after 100 min at 25C
displayed significant cytotoxicity, whereas the peptide in-
cubated in the aggregation solution at 4.0C started to be
significantly cytotoxic only after 3 h of aging, in agreement
with its slower aggregation kinetics. Moreover, aggregate
toxicity progressively decreased with aggregation time, the
reduction being more evident for aggregates aged at 25C
than for aggregates aged at 4.0C (Fig. 6 B), concomitant
with the increasing presence of fibrillar material. A dose-
dependence analysis of aggregate toxicity was also per-
formed by incubating the cells for 24 h with different
amounts (12.0, 4.0, 2.0, and 0.4 mM, monomeric protein
concentration) of p53(1–63) aggregates aged in 20 mM
FIGURE 4 Tapping-mode AFM im-
ages (height data) of p53(1–63)N-terminal
domain aggregated at 4.0C and pH 3.0
for (A) 20 min, (B) 3.0 h, or (C and D)
24 h. Scan size: (A) 5.0 mm; (B) 1.0 mm;
(C) 1.9mm; (D) 0.68mm. Z range 10 nm.
The corresponding aggregate height dis-
tributions are shown in the insets. (D)
Inset is a 250 nm 3 240 nm portion of
the corresponding amplitude data image
(scan size 0.68 mm) showing the sphe-
roidal structure indicated by the black
square.
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citrate buffer, pH 3.0, at 25C for 100 min. In these condi-
tions, the toxicity was progressively reduced with the de-
crease of aggregate concentration, becoming irrelevant at
2 mM, which can be taken as the lower limit of toxicity under
our conditions (Fig. 6 C).
We then sought to assess whether cell stress given by the
aggregates resulted in membrane disruption and/or apoptotic
activation. First, we performed a membrane integrity test in
exposed cells by assaying the LDH release in the culture
medium during cell exposure to p53(1–63) aggregates ob-
tained by incubating the domain at pH 3.0 for 100 min at
25C or at 4.0C, respectively. Fig. 7 A shows no LDH re-
lease in the medium from cells exposed to aggregates aged at
both temperatures as compared with control cells, indicating
that aggregate toxicity does not result in cell disruption. To
check whether cell impairment after exposure to the aggre-
gates matched the activation of the apoptotic pathway, we
assayed the activity of caspase-3, a major executioner cas-
pase, in cells exposed for 24 h to the aggregates. Both 100%
and 50% increases in caspase-3 activity were observed in
cells treated with aggregates aged for 100 min at 4.0C or at
25C, respectively (Fig. 7 B), in agreement with previously
reported data for these and other cell cultures exposed to
HypF-N prefibrillar aggregates (35–37). At these times the
extent of apoptotic activation did not match the MTT test
values, being higher in cells exposed to aggregates aged at
4.0C. However, it must be taken into account that the MTT
test is a measure of cell viability in terms of mitochondrial
functionality, whereas the activation of caspase-3 can also
result from the extrinsic pathway starting from cell mem-
brane signals; under our conditions, it is likely that the ex-
trinsic apoptotic pathway is triggered by aggregates added to
the cell culture that are likely to interact with the cell mem-
brane, as has been repeatedly reported (36,37). This agrees
with the slower kinetics of the aggregation process at 4.0C
than at 25C, suggesting that the aggregates arising at 4.0C
after 100 min of incubation display less ordered structural
features, favoring their interaction with the cell membrane.
DISCUSSION
The N-terminal domain of p53 displays the canonical fea-
tures of an intrinsically disordered protein with important
implications for the functional mechanism of the whole p53
protein and is involved in p53 turnover by binding mdm2.
p53 mediates transcription signals by forming complexes
with several proteins before transcription initiation. In this
study, we analyzed the structural properties of the purified
p53 N-terminal transactivation domain (residues 1–63) using
different approaches. The results from FT-IR, ThT, and ANS
spectroscopy, AFM, and x-ray diffraction show that, when it
is incubated at low pH, this domain acquires an ordered
secondary structure aggregating reproducibly into amyloid-
like fibrils, in agreement with other unstructured proteins rich
in acidic residues (38,39).
FIGURE 5 (A) Tapping-mode AFM image (height data) of mature
p53(1–63) fibrils. Scan size 3.1 mm, Z range 10 nm. (B) Height distribu-
tion of mature p53 fibrils showing the coexistence of fibril populations of
different sizes. (C) X-ray diffraction diagram of p53(1–63) fibrils collected
on sedimented fibrillar aggregates showing the equatorial and meridional
reflections at 4.5 and 10.0 A˚, respectively, characteristic of the cross-
b-structure.
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FT-IR analysis showed that, at low pH, the natively un-
folded p53(1–63) acquires a transient partially folded con-
formation as shown by either the decrease in absorbance at
1641 cm1 (typical of the unfolded structure) and the in-
creases at 1652 and 1635 cm1, indicative of a-helix and
intramolecular b-sheet, respectively. A transitory increase in
a-helix is not unusual during amyloid aggregation; for in-
stance, human amylin aggregation in the presence of lipid
membranes (a condition resembling that of its aggregation in
vivo) proceeds through a transitory shift from unfolded to
mainly a-helical before conversion into b-amyloid structure
(40). Similarly, the partial helical structure initially found in
the amyloid-b peptides in the presence of critical concen-
trations of organic solvents increases the rate of amyloid fibril
formation, possibly by favoring the intermolecular packing
FIGURE 7 (A) Evaluation of SH-SY5Y necrosis after cell exposure to
p53(1–63) aggregates. Cells were treated for 24 h with 12.0 mM p53(1–63)
aggregates obtained by incubating the peptide in 20 mM citrate buffer, pH
3.0, for 100 min at 25C or 4.0C. LDH release in the culture medium after
necrotic rupture of the cell membrane was determined by an assay coupled to
the oxidation of the fluorescent dye Resazurin. For each sample, LDH
activity in the medium was normalized with respect to total LDH activity
determined after cell lysis. (B) Evaluation of SH-SY5Y apoptosis after cell
exposure to p53(1–63) aggregates. Cells were treated as above, and their
caspase-3 activity was determined using the fluorescent substrate Ac-
DEVD-AMC. Data obtained from three different experiments carried out
under identical conditions were normalized with respect to the value of
controls (cells treated with the same concentration of soluble p53(1–63)),
which was taken as 100%. SEM is reported. Statistical analysis was
performed comparing the value of every treatment with respect to control
by means of the Dunnett multiple-comparisons test. *p, 0.05; **p, 0.01.
FIGURE 6 Evaluation of p53(1–63) cytotoxicity by the MTT reduction
assay. (A and B) Human SH-SY5Y cells were exposed for 24 h to 12.0 mM
p53(1–63) aggregates obtained by incubating the peptide in 20 mM citrate
buffer, pH 3.0, at 4.0C or 25C for increasing lengths of time. (C) The cells
were exposed to different concentrations of p53(1–63) aggregates obtained
by incubating the peptide at 0.4 mg/ml in 20 mM citrate buffer, pH 3.0, for
100 min at 25C. Control cells were treated with 12.0 mM native p53(1–63).
Cytotoxicity was evaluated by the MTT reduction assay (see Materials and
Methods). Data, obtained from three different experiments carried out under
identical conditions, were normalized with respect to the absorbance of the
controls, which was taken as 100% for each experiment; SEM is reported.
Statistical analysis was performed comparing the value of every treatment
with respect to control by means of the Dunnett multiple-comparisons test.
*p , 0.05; **p , 0.01.
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within the oligomers (41). Subsequently, a decrease of the
a-helix component accompanied by a striking increase in the
signal around 1615 and 1683 cm1 indicative of intermo-
lecular b-structure was seen in p53(1–63). This transition
could be favored by a decrease of the intramolecular elec-
trostatic repulsions at pH values approaching the isoelectric
point, with the increased availability of the peptide backbone,
and by an increased strength of the hydrophobic interactions
resulting from the exposure of contiguous hydrophobic sur-
faces, as confirmed by the positivity of the ANS test. These
structural modifications of the unfolded p53(1–63) are con-
sistent with the fact that, in general, amyloid fibril formation
requires both secondary and tertiary interactions to be es-
tablished among monomers. Actually, in vitro amyloido-
genesis from folded proteins is frequently observed to occur
under mild destabilizing conditions still favoring secondary
interactions established by the peptide backbone (42) but
only partially weakening the tertiary ones.
Under our experimental conditions, oligomers and fibrils
were predominantly populated in the aggregation medium
after a few hours or from day 2 of incubation, respectively, as
shown by AFM, ThT, and ANS binding. The oligomers
converted into fibrils during aging in the aggregation medium
in agreement with the current view on the mechanisms of
amyloid formation (42,43). Subsequent fibril maturation
resulting in fibril thickening, as measured by AFM, was
possibly related to an increase of the number of protofila-
ments.
Amyloid oligomers obtained at different times of incuba-
tion of p53(1–63) in acidic conditions impair SH-SY5Y cell
viability, a cell model previously shown to be highly vul-
nerable to amyloid toxicity (37). When cells were treated for
24 h with amyloid oligomers obtained at different times of
incubation in acidic conditions, cell stress was revealed by
the inhibition of MTT reduction and by caspase-3 activation.
Under these conditions, we did not observe any LDH release
from the exposed cells, suggesting that apoptosis was most
likely triggered through the activation of signal transduction
pathways at the cell surface without membrane disruption
(35,44). However, our preliminary observations suggest that
samples of p53(1–63) aged in acidic conditions for longer
time periods can induce a necrosis-like cell death as indicated
by the increase in LDH release in the culture medium (data
not shown), suggesting that mature amyloid fibrils could be
cytotoxic even through a less specific mechanism. Cell ne-
crotic death triggered by amyloid fibrils has previously been
reported in some cases (45,46).
The formation of off-pathway, nonfunctional partially
structured protein folding variants is referred to as kinetic
misfolding (47); in the case of several wild-type proteins
found aggregated in human diseases such as senile systemic
amyloidosis and some types of cancer, the latter often results
in the aggregation of the off-pathway intermediates (48). This
mechanism is attractive in the case of p53 because it de-
scribes how a population of natively folded, biologically
active molecules can acquire a nonfunctional, aggregation-
prone state over time. It is known that aggregates of p53,
either wild type or, more frequently, containing specific
mutations are found in many tumor cells (49). Recently, the
possible origin of these aggregates from any perturbation of
the folded/unfolded transition equilibrium of the p53 DNA
binding domain has been highlighted. The latter equilibrium
seems to involve a partially folded intermediate with in-
creased exposure of the hydrophobic core, which undergoes
reversible aggregation into a 10- to 20-mer. This finding can
explain the tendency of p53 to depart from the native state to
an inactive one undergoing aggregation and making the cell
susceptible to malignant transformation (49). Under mild
denaturing conditions, the DNA binding domain and a pep-
tide from a mutant of the tetramerization domain are also able
to form b-sheet-rich fibrillar aggregates very similar to those
found in amyloid diseases (50–52) and endowed with similar
cytotoxicity (50,53).
These and our data support the idea that p53 may be in-
volved in tumor genesis by losing its biological function in
two ways: a loss of the antitumor function of the wild-type or
mutated protein and/or a possible gain of function increasing
the aggregation potential of the misfolded mutant or wild-
type p53; once present, p53 aggregates can propagate the
structural alteration to other functional, correctly folded p53
molecules in a prion-like way, as already suggested (9,49).
This parallelism is further strengthened by a computational
analysis revealing a high similarity of p53 and PrP hydro-
phobicity patterns in terms of marked departure from random-
ness, at odds with the majority of proteins (54). Such highly
deterministic hydrophobicity patterns can easily be perturbed
by single amino acid substitutions, and this is the reason why
both proteins present an unusually low ratio of polymor-
phisms (i.e., silent mutations/total mutations).
The lack of functional p53 by these or other mechanisms
can be considered one of the fundamental events favoring
malignant transformation of a cell. In this perspective, our
results on an isolated domain under in vitro conditions are of
interest, showing for the first time that even the p53N-terminal
domain can potentially aggregate into cytotoxic amyloid as-
semblies. It could be argued that our in vitro observations
lack physiological relevance because p53(1–63) was made to
fibrillize in vitro at low pH. However, some cellular com-
partments, e.g., endosomes and lysosomes, associated with
protein translocation and degradation, respectively, are char-
acterized by a low internal pH. In addition, the anionic
phospholipids found in the inner leaflet of the cell membrane
have been proposed to be potent inductors of b-sheet struc-
tures by acting as conformational catalysts for amyloids (55).
The local low pH found near negatively charged lipid
membranes favors partial unfolding, and hence formation of
aggregation-prone intermediates, of adsorbed protein mole-
cules (56). Moreover, it cannot be excluded that the aggre-
gation of the whole p53 can be favored even at physiological
pH values by the excluded volume effects associated with the
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macromolecular crowding of the intracellular environment
(57). Under these conditions, aggregation could possibly start
from the unstructured N-terminal domain in some functional
state where it is not associated with mdm2, in agreement with
other examples of unfolded domain-driven aggregation (58–
61). Finally, because of the aggregation propensity of the
tetramerization and the core domain (51,52), some coopera-
tivity among p53 domains in favoring aggregation under in
vivo conditions and/or in the presence of suitable mutations
could be hypothesized.
Actually, the majority of cancer-associated p53 mutations
are located within the DNA-binding domain and the tetra-
merization domain. However, the IARC TP53 Mutation
Database (http://www-p53.iarc.fr) reports that some muta-
tions within the N-terminal domain of p53 are also associated
with human cancer. Many of these mutations, which are not
implicated in the transcriptional activity of the N-terminal
domain, could potentially perturb the p53 aggregation rate
according to a previously reported algorithm (62). Such a
formula evaluates the intrinsic contribution of any amino acid
substitution to the aggregation kinetics of an unfolded poly-
peptide chain (Table 1), considering the resulting quantitative
modification of hydrophobicity, net charge, and propensity to
form a b-sheet. The possibility that these mutations can favor
the aggregation of p53(1–63) or even of the whole protein,
under conditions closer to the physiological ones, is currently
under investigation. In conclusion, the propensity of the
N-terminal domain of p53 to form amyloid aggregates could
help to explain the susceptibility of p53 to undergo in vivo
structural modification from the native to an inactive aggre-
gated state, making the cell highly vulnerable to malignant
transformation.
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